Suzhou Highfine Biotech Co., Ltd. (SHE:301393)

Market Cap	6.88B +38.5%
Revenue (ttm)	638.98M +28.9%
Net Income	113.30M -18.5%
EPS	1.05 -17.8%
Shares Out	107.18M
PE Ratio	61.05
Forward PE	n/a
Dividend	0.41 (0.64%)
Ex-Dividend Date	May 21, 2026

Volume	1,985,556
Average Volume	2,378,384
Open	63.10
Previous Close	63.50
Day's Range	62.32 - 64.36
52-Week Range	46.69 - 66.23
Beta	0.70
RSI	65.33
Earnings Date	Aug 28, 2026

About Suzhou Highfine Biotech

Suzhou Highfine Biotech Co., Ltd. manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China. The company’s products include building blocks, protein reagents, protein crosslinkers, peptide reagents, protective amino acids, ionic liquids, PROTAC reagents, unnatural amino acids, pharmaceutical reagents of liposomes and lipid nanoparticles, nucleotide reagents, etc. Its products are used in fields of peptide, nucleotide, and pharmaceutical synthesis. The company also exports its products. S...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 678
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301393

Financial Performance

In 2025, Suzhou Highfine Biotech's revenue was 602.26 million, an increase of 33.28% compared to the previous year's 451.87 million. Earnings were 114.65 million, a decrease of -14.47%.